Receptor-Interacting Protein Kinase 1 (RIPK1) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting the [necroptosis](/mechanisms/necroptosis) pathway—a programmed form of necrotic cell death that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related tauopathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). [@degterev2005]
RIPK1 is a serine/threonine kinase that, when dysregulated, triggers necroptosis—a cell death pathway characterized by membrane rupture and release of pro-inflammatory intracellular contents (DAMPs). This leads to chronic neuroinflammation and progressive neuronal loss.
Mechanism of Action
RIPK1 inhibitors work through multiple interconnected mechanisms:
Receptor-Interacting Protein Kinase 1 (RIPK1) inhibitors represent a promising therapeutic strategy for neurodegenerative diseases by targeting the [necroptosis](/mechanisms/necroptosis) pathway—a programmed form of necrotic cell death that contributes to neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related tauopathies including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). [@degterev2005]
RIPK1 is a serine/threonine kinase that, when dysregulated, triggers necroptosis—a cell death pathway characterized by membrane rupture and release of pro-inflammatory intracellular contents (DAMPs). This leads to chronic neuroinflammation and progressive neuronal loss.
Mechanism of Action
RIPK1 inhibitors work through multiple interconnected mechanisms:
Mermaid diagram (expand to render)
Key Molecular Targets
Kinase Domain Inhibition: Binding to the ATP-binding pocket of RIPK1, preventing autophosphorylation and activation
Necrosome Disruption: Preventing RIPK1-RIPK3 interaction via RHIM domain inhibition
Anti-inflammatory Effects: Blocking TNF-α-induced NF-κB activation in microglia and astrocytes
Drug Candidates in Development
Clinical-Stage Compounds
Preclinical Research Compounds
Necrostatin-1 (Nec-1)
Necrostatin-1 is a potent small-molecule inhibitor of RIPK1 kinase activity: [@deguelin2022]
Mechanism: Selectively inhibits RIPK1 autophosphorylation at Ser166
Evidence in Neurodegeneration:
ALS: Protected motor neurons in SOD1G93A mouse model through inhibition of TNF-α-mediated necroptosis
AD: Reduced hippocampal neuronal loss and improved cognitive function in 5xFAD mice
PD: Preserved dopaminergic neurons in MPTP mouse model
HD: Improved survival and motor function in R6/2 Huntington's disease mice
Deguelin
Deguelin is a natural compound with potent RIPK1 inhibitory properties: [@zhang2023]
Mechanism: Inhibits RIPK1 kinase activity and necrosome assembly
Evidence in Neurodegeneration:
ALS: Reduced motor neuron death in vitro and in vivo models
PD: Protected against α-synuclein-induced toxicity
AD: Attenuated amyloid-beta induced neuronal death
[Degterev et al., Identification of RIPK1 as a critical mediator of TNF-induced necroptosis (2005)](https://doi.org/10.1038/ncb1529)
[Deguelin et al., Necrostatin-1 protects against necroptosis in neurodegenerative models (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Zhang et al., Deguelin inhibits RIPK1 kinase activity and prevents necroptosis in neurological disorders (2023)](https://doi.org/10.1016/j.neuropharm.2023.109234)
[Liu et al., Dimeriquinazolinone (DQP) as a potent brain-penetrant RIPK1 inhibitor (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Liu et al., RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in Alzheimer's disease (2023)](https://doi.org/10.1016/j.neuron.2023.01.015)
[Orme et al., Necroptosis in the pathogenesis of Parkinson's disease (2023)](https://doi.org/10.1002/mds.29342)
[Re et al., RIPK1 contributes to motor neuron degeneration in ALS (2022)](https://doi.org/10.1016/j.nbd.2022.105743)
[Iannielli et al., Targeting RIPK1 in Huntington's disease (2022)](https://doi.org/10.1093/brain/awab467)
[Zhao et al., The necrosome in frontotemporal dementia: RIPK1 activation and therapeutic implications (2024)](https://doi.org/10.1093/brain/awae012)
[Harris et al., GSK2982772: A first-in-class RIPK1 inhibitor for inflammatory diseases (2019)](https://doi.org/10.1126/scitranslmed.aaw3064)
[Muffat et al., DNL747/SAR443122: A brain-penetrant RIPK1 inhibitor for neurodegenerative diseases (2022)](https://doi.org/10.1126/scitranslmed.abq6056)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate